Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
journalStr:"Lancet (London, England)"
topic_facet:"Research Support, Non-U.S. Gov't"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=journalStr%3A%22Lancet+%28London%2C+England%29%22&filter%5B%5D=topic_facet%3A%22Research+Support%2C+Non-U.S.+Gov%27t%22&lookfor=%22Clinical+Trial%2C+Phase+III%22&type=Subject
/vufind/Search/Results?filter%5B%5D=journalStr%3A%22Lancet+%28London%2C+England%29%22&filter%5B%5D=topic_facet%3A%22Research+Support%2C+Non-U.S.+Gov%27t%22&lookfor=%22Clinical+Trial%2C+Phase+III%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=journalStr%3A%22Lancet+%28London%2C+England%29%22&filter%5B%5D=topic_facet%3A%22Research+Support%2C+Non-U.S.+Gov%27t%22&lookfor=%22Clinical+Trial%2C+Phase+III%22&type=Subject
PubPharm (321)
1
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France : a phase 3, open-label, randomised controlled trial
enthalten in:
Lancet (London, England)
| 2023
von
Chu, Q.
|
Perrone, F.
|
Greillier, L.
| +32
CommentIn: Lancet. 2023 Dec 16;402(10419):2266-2267. - PMID 37931626
Wird geladen...
2
Ubrogepant for the treatment of migraine attacks during the prodrome : a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA
enthalten in:
Lancet (London, England)
| 2023
von
Dodick, D.
|
Goadsby, P.
|
Schwedt, T.
| +7
Wird geladen...
3
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma : interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
enthalten in:
Lancet (London, England)
| 2023
von
Janjigian, Y.
|
Kawazoe, A.
|
Bai, Y.
| +18
CommentIn: Lancet. 2023 Dec 9;402(10418):2168-2170. - PMID 37871605
Wird geladen...
4
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT) : 2-year results from a randomised, active-controlled, phase 3 trial
enthalten in:
Lancet (London, England)
| 2023
von
Rovin, B.
|
Barratt, J.
|
Heerspink, H.
| +130
CommentIn: Lancet. 2023 Dec 2;402(10417):2046-2047. - PMID 37931627
Wird geladen...
5
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050) : a randomised, open-label, multicentre, phase 3 trial
enthalten in:
Lancet (London, England)
| 2023
von
Qin, S.
|
Chen, M.
|
Cheng, A.
| +122
CommentIn: Lancet. 2023 Nov 18;402(10415):1806-1807. - PMID 37883983
Wird geladen...
6
Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS) : a randomised, double-blind, placebo-controlled, phase 3 trial
enthalten in:
Lancet (London, England)
| 2023
von
Ford, A.
|
Wright-Hughes, A.
|
Alderson, S.
| +66
CommentIn: Lancet. 2023 Nov 11;402(10414):1727-1728. - PMID 37858321
Wird geladen...
7
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV) : a multicentre, randomised, placebo-controlled, phase 3 trial
enthalten in:
Lancet (London, England)
| 2023
von
Broome, C.
|
McDonald, V.
|
Miyakawa, Y.
| +83
Wird geladen...
8
Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6) : a phase 3a, randomised, open-label, treat-to-target trial
enthalten in:
Lancet (London, England)
| 2023
von
Russell-Jones, D.
|
Babazono, T.
|
Cailleteau, R.
| +7
CommentIn: Lancet. 2023 Nov 4;402(10413):1598-1599. - PMID 37863082
Wird geladen...
9
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02) : a randomised, open-label, multicentre, phase 3 trial
enthalten in:
Lancet (London, England)
| 2023
von
Rugo, H.
|
Bardia, A.
|
Marmé, F.
| +15
CommentIn: Nat Rev Clin Oncol. 2023 Nov;20(11):734. - PMID 37684406
Wird geladen...
10
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310) : a randomised, open-label, international phase 3 study
enthalten in:
Lancet (London, England)
| 2023
von
Qin, S.
|
Chan, S.
|
Gu, S.
| +132
CommentIn: Lancet. 2023 Sep 30;402(10408):1108-1110. - PMID 37499669
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[33]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Zeitschrift: Lancet (London, England)
Filter aufheben
Thema: Research Support, Non-U.S. Gov't
Medienart
321
Aufsätze
309
E-Artikel
309
E-Ressourcen
12
Gedruckte Aufsätze
Zeitschriftentitel
Lancet (London, England)
Thema
321
Clinical Trial, Phase III
Research Support, Non-U.S. Gov't
320
Journal Article
317
Randomized Controlled Trial
264
Multicenter Study
89
Comparative Study
55
Antibodies, Monoclonal, Humanized
39
Antibodies, Monoclonal
38
Antineoplastic Agents
20
Research Support, N.I.H., Extramural
18
0W860991D6
18
Klinische Studie
18
Deoxycytidine
15
EC 2.7.10.1
15
Hypoglycemic Agents
14
Anti-HIV Agents
14
Fluorouracil
14
U3P01618RT
13
8N3DW7272P
13
Cyclophosphamide
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
307
2000-
6
1900-1999
Erscheinungsjahr(e)
Von:
Bis:
Sprache
321
Englisch
Haven't found what you're looking for?
Wird geladen...